Design Therapeutics, Inc. Investment Income, Interest
Design Therapeutics, Inc. (DSGN) reported Investment Income, Interest of $2.01 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2026-08-03
- Design Therapeutics, Inc. investment income, interest for the quarter ending 2026-06-30 was $2.01M, a 19.07% decline year-over-year.
- Design Therapeutics, Inc. investment income, interest for the quarter ending 2026-03-31 was $2.07M, a 23.42% decline year-over-year.
- Design Therapeutics, Inc. investment income, interest for the quarter ending 2025-12-31 was $2.17M, a 28.62% decline year-over-year.
- Design Therapeutics, Inc. investment income, interest for the quarter ending 2025-09-30 was $2.31M, a 27.85% decline year-over-year.
- Design Therapeutics, Inc. investment income, interest for fiscal 2025 was $9.68M, a 24.38% decline from fiscal 2024.
- Design Therapeutics, Inc. investment income, interest for fiscal 2024 was $12.79M, a 12.95% increase from fiscal 2023.
- Design Therapeutics, Inc. investment income, interest for fiscal 2023 was $11.33M.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month | Investment Income, Interest 9 month | Investment Income, Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.01M 10-Q · filed 2026-08-03 | $4.08M 10-Q · filed 2026-08-03 | $6.25M derived: sum of 3 quarters · filed 2026-08-03 | $8.57M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | $2.07M 10-Q · filed 2026-04-28 | $4.24M derived: sum of 2 quarters · filed 2026-04-28 | $6.56M derived: sum of 3 quarters · filed 2026-04-28 | $9.04M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | $2.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $4.49M derived: sum of 2 quarters · filed 2026-03-09 | $6.97M derived: sum of 3 quarters · filed 2026-08-03 | $9.68M 10-K · filed 2026-03-09 |
| 2025-09-30 | $2.31M 10-Q · filed 2025-11-05 | $4.80M derived: sum of 2 quarters · filed 2026-08-03 | $7.50M 10-Q · filed 2025-11-05 | $10.55M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | $2.49M 10-Q · filed 2026-08-03 | $5.19M 10-Q · filed 2026-08-03 | $8.23M derived: sum of 3 quarters · filed 2026-08-03 | $11.44M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $2.70M 10-Q · filed 2026-04-28 | $5.75M derived: sum of 2 quarters · filed 2026-04-28 | $8.95M derived: sum of 3 quarters · filed 2026-04-28 | $12.20M derived: sum of 4 quarters · filed 2026-04-28 |
| 2024-12-31 | $3.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $6.25M derived: sum of 2 quarters · filed 2026-03-09 | $9.50M derived: sum of 3 quarters · filed 2026-03-09 | $12.79M 10-K · filed 2026-03-09 |
| 2024-09-30 | $3.21M 10-Q · filed 2025-11-05 | $6.46M derived: sum of 2 quarters · filed 2025-11-05 | $9.75M 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $3.25M 10-Q · filed 2025-08-07 | $6.54M 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | $3.29M 10-Q · filed 2025-05-07 | |||
| 2023-12-31 | $11.33M 10-K · filed 2025-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |